Cell therapy weekly: US FDA clears IND application for a controllable cell therapy for multiple myeloma

This week: the US FDA has cleared an IND application for ACLX-001, an engineered cell therapy for the treatment of multiple myeloma; Health Canada has given permission to BlueRock Therapeutics to initiate a Phase I tolerability study of MSK-DA01 cell therapy for advanced Parkinson’s disease; and TrakCel has announced the creation of OCELLOS, their second-generation, Salesforce-powered cellular orchestration platform. The news highlights: US FDA clears IND application for a controllable cell therapy for multiple myeloma BlueRock receives permission from Health Canada to initiate DA01 trial in Parkinson’s disease OCELLOS: TrakCel announces second-generation, Salesforce-powered cellular orchestration platform   US FDA clears...